Biohaven Pharma (BHVN) Misses Q2 EPS by 172c

Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($3.50), $1.72 worse than the analyst estimate of ($1.78).

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Corporación América Airports S.A. (CAAP) Misses Q2 EPS by 18c
• JPMorgan Downgrades Reliance Worldwide Corp Ltd (RWC:AU) (RLLWF) to Neutral
• Gaming and Leisure (GLPI) Reiterated at Market Outperform by Citizens